帕瑞昔布钠对骨代谢的影响及丙泊酚的干预作用  

Effects of parecoxib on bone metabolism of rats and intervention of propofol

作　　者：黄海城[1] 宋伏虎[1] 李传翔[1] 赵天云[1] 陈力[1] 

机构地区：[1]南方医科大学第三附属医院南方医科大学第三临床医学院,广州510630

出　　处：《中华实验外科杂志》2014年第1期138-141,共4页Chinese Journal of Experimental Surgery

基　　金：广东省自然科学基金资助项目（$2012010009107）

摘　　要：目的 观察帕瑞昔布钠对大鼠骨代谢的影响及丙泊酚对其的干预作用.方法 动物实验：32只成年SD雌鼠,随机分为4组（n=8）：对照组（Control组）、选择性环氧合酶-2（COX-2）抑制剂组（Parecoxib组）、静脉麻醉药组（Propofol组）、选择性COX-2抑制剂和静脉麻醉药混合处理组（Mixture组）.胫骨损伤术后,每日给药,早晚间隔12h,各1次,连续7d.给药完成后1、2、5、8周测量大鼠术侧胫骨骨密度（BMD）及1、2周检测血清骨钙素（OC）水平.细胞实验：将鼠源成骨样细胞株MC3T3-E1诱导分化后分为4个处理组,Control、Parecoxib、Propofol和Mixture组,每个处理组分为3个亚处理浓度：分别以1、10、100 μmol/L浓度药物处理.药物处理3d后,采用Western blot法分别检测成骨细胞骨保护素（OPG）和核因子（NF）-κB受体活化因子配体（RANKL）的蛋白质表达水平.结果 动物实验：给药完成2周,帕瑞昔布钠处理组骨密度测量值明显降低,Parecoxib组：0.091 5 ±0.0037,Control组：0.111 8±0.0064,两组比较差异有统计学意义（P＜0.05）；给药完成后1周和2周,丙泊酚处理组血清OC均明显高于其他3个处理组,1周Propofol组：907.1370±109.923 9,2周Propofol组：1 036.863 0±15.551 4,分别与其他组比较差异有统计学意义（P＜0.05）；给药完成后2周,混合处理组血清OC明显高于对照组和帕瑞昔布钠处理组,Mixtrue组：951.165 0±85.886 3,Control组：736.916 7±34.687 4,Parecoxib组：813.571 7±63.712 2,组间比较差异有统计学意义（P＜0.05）.细胞实验：100、10μmol/L浓度的帕瑞昔布钠组RANKL蛋白明显减少（P＜0.05）,所有浓度的帕瑞昔布钠处理组OPG蛋白表达均减少（P＜0.05）；100 μmol/L浓度的丙泊酚组RANKL蛋白明显增加（P＜0.05）,所有浓度的丙泊酚处理组OPG蛋白表达均增加（P＜0.05）；所有浓度的混合处理组RANKL蛋白与对照组比较差异无统计学意义（P＞0.05）,1μmol/L�Objective To observe the effects of parecoxib on the bone metabolism of rats and intervention of propofol.Methods Thirty-two SD female rats were randomly divided into four groups （n =8each）：control group,parecoxib group,propofol group and combination group.The rats were given the medicine intraperitoneally twice daily for 7 days after surgery.The bone mineral density （BMD） at the fracture site was measured using dual energy x-ray absorptiometry （DEXA） on the week one,two,five and eight.The level of serum osteocalcin （OC） was determined by using an enzyme linked immunosorbent assay （ELISA） on the week one and two.In the in vitro experiment,osteoblast-like cell line MC3T3-E1 cells were cultured,and divided into four groups：control group,parecoxib group,propofol group and combination group.Each group was sub-divided into three subgroups：1 μmol/L subgroup,10 μmol/L subgroup and 100 μmol/L subgroup.Western blotting was used to detect the expression of bone protection element （OPG） and receptor activator of nuclear factor-κB ligand （RANKL） proteins 3 days later.Results In the in vivo experiment,two weeks after surgery,the BMD in the parecoxib group （0.091 5 ± 0.003 7） was significantly lower than that in the control group （0.111 8 ± 0.006 4） （P 〈 0.05）.At each time point,the OC in the propofol group （907.137 0 ± 109.923 9） at the first week,and 1 036.863 0 ± 15.551 4 at the second week） was significantly higher than that in the other three groups at each time point （P 〈 0.05for all）.Two weeks later,the OC in the combination group,control group and parecoxib group were respectively 951.165 0 ±85.886 3,736.916 7 ±34.687 4 and 813.571 7 ±63.712 2 respectively.The OC in the combination group was significantly higher than that in both control group and parecoxib group （P 〈0.05）.In thein vitro experiment,RANKL protein in the parecoxib group was significantly lower at the concentrations of 10 μmol/L and 100 μmol/L,and that in the propofol group was

关 键 词：帕瑞昔布钠 丙泊酚 骨代谢 骨密度 骨保护素 

分 类 号：R614[医药卫生—麻醉学]